Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

GlyCanDrug A training network on the design of precision therapeutics that target key glycan motifs implicated in cancer

Coordinator
Universita Degli Studi Di Firenze, Italy
Runs
1 December 2023 to 30 November 2027
Status
Running
EU funding
€2.7m
Total cost
—
Partners
23 organisations in 11 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101119601

What the project is doing

In the project's own words, from its summary on CORDIS.

Glycoscience has gained such significant technological advances over the past decade, that it is now poised for giving an unprecedented contribution to high-demanding societal needs. GlyCanDrug is a glycoscience-oriented DN that aims, for the first time, to take a step ahead in the design of precision therapeutics targeting key glycan motifs implicated in cancer. These glycans are fingerprints of many cancers. Thus, their targeting has the striking potential to overcome cancer heterogeneity that limits the current targeted therapies providing new opportunities for the discovery of precision therapeutics.

The credibility and high quality of GlyCanDrug are ensured by top-level glycoscientists from 9 academic institutions (8EU & 1US) and 6 SMEs which encompass complementary and intersectoral expertise, and unique state-of-the-art technological tools to train 10 doctoral candidates (DCs). GlyCanDrug focuses on the precise inhibition of the expression of cancer-associated glycans and the development of cutting-edge tools for their targeting.

The unique combination of scientific excellence in interdisciplinary fields and industry know-how will cover the entire process from obtaining fundamental insights to the implementation of innovative solutions. GlyCanDrug aims at creating a critical mass of uniquely skilled graduates in glycan-based therapies. To this aim, we will equip DCs with a thorough multifaceted knowledge of the potential of glycoscience in the discovery of cancer precision therapeutics and the necessary transferable skills.

This will put DCs in an advantageous position for job opportunities in both academia and industry. Deciphering the glycome expands the frontiers of knowledge and discovery and enables addressing fundamental challenges in cancer. Therefore, GlyCanDrug DN will strengthen the European innovation capacity by bringing new glycoscience concepts in the development of cancer precision therapeutics to market and policy stakeholders.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di FirenzeFlorenceItalyCoordinator
Tuscan Organisation of Universitiesand Research 4 EuropeBruxelles / BrusselBelgiumAssociatedpartner
Crelux GmbHMartinsriedGermanyAssociatedpartner
Glyxera GmbHMagdeburgGermanyAssociatedpartner
Paia Biotech GmbHKolnGermanyAssociatedpartner
Combotope Therapeutics ApSKongens LyngbyDenmarkAssociatedpartner
Danmarks Tekniske UniversitetKongens LyngbyDenmarkParticipant
Glycodisplay ApsKobehavnDenmarkAssociatedpartner
Glycodisplay ApsKobehavnDenmarkParticipant
Kobenhavns UniversitetKobenhavnDenmarkAssociatedpartner
Kobenhavns UniversitetKobenhavnDenmarkParticipant
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
Universidad De SevillaSevillaSpainAssociatedpartner
Universidad De ZaragozaZaragozaSpainParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Universite De LilleLilleFranceAssociatedpartner
Carbohyde Zartkoruen Mukodo ReszvenytarsasagBudapestHungaryAssociatedpartner
Innovation Acta SRLSienaItalyAssociatedpartner
Cimaas BVMaastrichtNetherlandsAssociatedpartner
I3s - Instituto De Investigacao E Inovacao Em Saude Da Universidade Do PortoPortoPortugalParticipant
Universidade Do PortoPortoPortugalAssociatedpartner
Univerza V LjubljaniLjubljanaSloveniaParticipant
Florida International UniversityMiamiUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI